

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043960 A1

(51) International Patent Classification⁷: **C07D 471/08**,
A61K 31/551, A61P 25/00, 25/28, 25/16 // (C07D 471/08,
243:00, 237:00, 261:00, 275:00)

(21) International Application Number:
PCT/DK2003/000769

(22) International Filing Date:
10 November 2003 (10.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 01737 11 November 2002 (11.11.2002) DK

(71) Applicant: **NEUROSEARCH A/S** [DK/DK]; 93 Peder-
strupvej, DK-2750 Ballerup (DK).

(72) Inventors: **PETERS, Dan**; c/o NeuroSearch A/S, 93 Ped-
erstrupvej, DK-2750 Ballerup (DK). **OLSEN, Gunnar,**
M.; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750
Ballerup (DK). **NIELSEN, Elsebet, Østergaard**; c/o Neu-
roSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK).
JØRGENSEN, Tino, Dyhring; c/o NeuroSearch A/S,
93 Pederstrupvej, DK-2750 Ballerup (DK). **AHRING,**
Philip, K.; c/o NeuroSearch A/S, 93 Pederstrupvej,
DK-2750 Ballerup (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,

RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent
(BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

Published:

— *with international search report*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 1,4-DIAZABICYCLO (3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF

(57) Abstract: This invention relates to novel diazabicyclic biaryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.



WO 2004/043960 A1

NOVEL DIAZABICYCLIC BIARYL DERIVATIVES

TECHNICAL FIELD

5 This invention relates to novel diazabicyclic biaryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system
10 (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

15

BACKGROUND ART

The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors, the muscarinic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).

20

As it is well established that muscarinic acetylcholine receptors dominate quantitatively over nicotinic acetylcholine receptors in the brain area important to memory and cognition, and much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscarinic acetylcholine receptor modulators.

25

Recently, however, an interest in the development of nAChR modulators has emerged. Several diseases are associated with degeneration of the cholinergic system i.e. senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to the organic brain damage disease related directly to alcoholism. Indeed several CNS disorders can be attributed to a cholinergic deficiency, a
30 dopaminergic deficiency, an adrenergic deficiency or a serotonergic deficiency.

WO 00/34279, WO 01/92259, WO 01/92260, WO 01/92261, WO 03/044019, WO 03/044020, WO 03/044024 (Sanofi-Synthelabo), and DE 10162442 (Bayer AG) describe 1,4-diazabicyclo[3.3.2]nonane derivatives having affinity for nicotinic receptors.

35

SUMMARY OF THE INVENTION


The present invention is devoted to the provision novel modulators of the nicotinic and/or of the monoamine receptors, which modulators are useful for the

treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine receptor (nAChR), the serotonin receptor (5-HT₁), the dopamine receptor (DAR) and the norepinephrine receptor (NER), and of the biogenic amine transporters for serotonin (5-HT), dopamine (DA) and norepinephrine (NE).

Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.


The compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for *in vivo* receptor imaging (neuroimaging), and they may be used in labelled or unlabelled form.

In its first aspect the invention provides novel diazabicyclic biaryl derivatives represented by Formula I




any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein n is 1, 2 or 3; and

'A' represents a bivalent phenyl group of the formula




; or

'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from



wherein X represents O, S or Se; and R' represents hydrogen or alkyl; or

'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from



B represents an aromatic monocyclic or bicyclic carbocyclic group; or

5 B represents a 5-6 membered aromatic monocyclic heterocyclic group; or

B represents an aromatic bicyclic heterocyclic group;

which monocyclic or bicyclic, carbocyclic or heterocyclic groups may

optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN,

10 amino and nitro; and a group for formula -NR''COR''', and -NR''SO₂R''', wherein R''

and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula -CONR''R''' and -SO₂NR''R'''

wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom

15 to which they are bound, form a heterocyclic ring;

provided however,

if A represents an isoxazol-3,5-diyl, a thiazol-2,5-diyl, a 1,2,4-oxadiazol-3,5-diyl, a 1,3,4-oxadiazol-2,5-diyl, a 1,3,4-thiadiazol-2,5-diyl, pyridin-2,5-diyl, or a pyridazin-3,6-diyl group, then B is not a phenyl or substituted phenyl group; or

20 if A represents a 1,2,4-oxadiazol-3,5-diyl group, then B is not a substituted or non-substituted thienyl, furanyl, pyridinyl, or benzothienyl group.

In its second aspect the invention provides pharmaceutical compositions comprising a therapeutically effective amount of the diazabicyclic biaryl derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, together with at

25 least one pharmaceutically-acceptable carrier or diluent.

In a further aspect the invention relates to the use of the diazabicyclic biaryl derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition/medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors.

In a final aspect the invention provides methods of treatment, prevention or alleviation of diseases, disorders or conditions of a living animal body, including a


human, which disorder, disease or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the diazabicyclic biaryl derivative of the invention.

- 5 Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.

DETAILED DISCLOSURE OF THE INVENTION

10 Diazabicyclic Biaryl Derivative


In a first aspect novel diazabicyclic biaryl derivatives are provided. The diazabicyclic biaryl derivatives of the invention may be represented by the general Formula I



- 15 any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein


n is 1, 2 or 3; and

'A' represents a bivalent phenyl group of the formula




; or


- 20 'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




, and



, and



, and




(read

in the direction represented by ' and '');

- 25 wherein X represents O, S or Se; and R' represents hydrogen or alkyl; or

'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from

5



B represents an aromatic monocyclic or bicyclic carbocyclic group; or

5 B represents a 5-6 membered aromatic monocyclic heterocyclic group; or

B represents an aromatic bicyclic heterocyclic group;

which monocyclic or bicyclic, carbocyclic or heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom


10 15 to which they are bound, form a heterocyclic ring;

provided however,

if A represents an isoxazol-3,5-diyl, a thiazol-2,5-diyl, a 1,2,4-oxadiazol-3,5-diyl, a 1,3,4-oxadiazol-2,5-diyl, a 1,3,4-thiadiazol-2,5-diyl, pyridin-2,5-diyl, or a pyridazin-3,6-diyl group, then B is not a phenyl or substituted phenyl group; or

20 if A represents a 1,2,4-oxadiazol-3,5-diyl group, then B is not a substituted or non-substituted thienyl, furanyl, pyridinyl, or benzothienyl group.

In a preferred embodiment the diazabicyclic biaryl derivative of the invention is a compound of Formula II



25 wherein 'A' and B are as defined above.

In another preferred embodiment the diazabicyclic biaryl derivative of the invention is a compound of Formula I or Formula II, wherein

'A' is as defined above and

B represents an aromatic monocyclic or bicyclic carbocyclic group, which aromatic group may optionally be substituted one or more times with substituents

30

selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halogen, CF₃, OCF₃, CN, amino and nitro; or

B represents a 5-6 membered aromatic monocyclic heterocyclic group, which aromatic group may optionally be substituted one or more times with
5 substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halogen, CF₃, OCF₃, CN, amino and nitro; or

B represents an aromatic bicyclic heterocyclic group, which bicyclic heterocyclic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy,
10 cyanoalkyl, halogen, CF₃, OCF₃, CN, amino and nitro.

In a more preferred embodiment the diazabicyclic biaryl derivative of the invention is a compound of Formula II wherein 'A' is as defined above; and


B represents a 5-6 membered aromatic monocyclic heterocyclic group; or

B represents an aromatic bicyclic heterocyclic group;

15 which monocyclic or bicyclic heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or
20 phenyl; and a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring.

In another preferred embodiment the diazabicyclic biaryl derivative of the
25 invention is a compound of Formula I or Formula II, wherein B represents a phenyl or naphthyl group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halogen, CF₃, OCF₃, CN, amino and nitro.

In a third preferred embodiment the diazabicyclic biaryl derivative of the
30 invention is a compound of Formula II wherein 'A' represents a 5-membered aromatic monocyclic heterocyclic group selected from




35 wherein X represents O, S or Se; and R' represents hydrogen or alkyl; and

B represents an aromatic monocyclic or bicyclic carbocyclic group, which monocyclic or bicyclic carbocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring.

10 In a more preferred embodiment

'A' represents a 5-membered aromatic monocyclic heterocyclic group selected from




wherein R' represents hydrogen or methyl; and

B represents a phenyl or naphthyl group, which aromatic group may optionally be substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.


In an even more preferred embodiment

'A' represents a 5-membered aromatic monocyclic heterocyclic group selected from


8



, and



, and




; and

B represents a phenyl or naphthyl group, which aromatic group may optionally be substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy, halo, CF_3 , OCF_3 , CN and nitro; and a group for formula

5 - $\text{NR}''\text{COR}'''$, and - $\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and a group of formula - $\text{CONR}''\text{R}'''$ and - $\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.


10 In a fourth preferred embodiment the diazabicyclic biaryl derivative of the invention is a compound of Formula I or Formula II wherein

'A' represents a bivalent phenyl group of the formula




; or


15 'A' represents a 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from:




, and




, and





, and




, and




, and



, and



,



and

(read in the direction represented by ' and '); and

B represents an aromatic monocyclic or bicyclic carbocyclic group; or

20 B represents a 5-6 membered aromatic monocyclic heterocyclic group; or


B represents an aromatic bicyclic heterocyclic group;

which monocyclic or bicyclic, carbocyclic or heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF_3 , OCF_3 , CN, amino and nitro; and a group for formula - $\text{NR}''\text{COR}'''$, and - $\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula - $\text{CONR}''\text{R}'''$ and - $\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl,

25


cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring.

In a more preferred embodiment 'A' represents a bivalent phenyl group of the formula




5 ; or


'A' represents a 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from




, and




, and




, and



,




, and




(read in the direction stated); and

10 B represents a phenyl or naphthyl group; or


B represents a 5-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




,




, and




, and




, and




, and




, and



, and



, and




;


15

wherein X represents O, S or Se; and R' represents hydrogen or alkyl; or


B represents a 6-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




, and



, and




, and



, and

20



; or


B represents an indolyl group;

which phenyl or naphthyl groups, or 5-6-membered monocyclic heterocyclic groups, or indolyl group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and a group for formula
 5 -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring; or

10 which phenyl or naphthyl groups, or 5-6-membered monocyclic heterocyclic groups, or indolyl group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halogen, CF₃, OCF₃, CN, amino and nitro.


In an even more preferred embodiment

15 'A' represents a bivalent phenyl group of the formula




; or


'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from



, and



, and




(read in the direction


20 stated); and

B represents a phenyl group; or


B represents a 5-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




,




, and




, and




, and




, and




, and




, and



, and




, and




,

and




, and



; or


B represents a 6-membered aromatic monocyclic heterocyclic group selected from




B represents an indol-2-yl, an indol-3-yl, an indol-5-yl or an indol-6-yl group;

5 which phenyl group, or 5-6-membered monocyclic heterocyclic groups, or indolyl groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halo, CF_3 , OCF_3 , CN and nitro; and a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and a group of formula
10 $-\text{CONR}''\text{R}'''$ and $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.

15 In a still more preferred embodiment 'A' represents a bivalent phenyl group of the formula




'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from




20 stated); and

B represents a phenyl group; or


B represents a 5-membered aromatic monocyclic heterocyclic group selected from



12



B represents a 6-membered aromatic monocyclic heterocyclic group selected from




B represents an indol-2-yl, an indol-3-yl, an indol-5-yl or an indol-6-yl group;


which phenyl group, or 5-6-membered monocyclic heterocyclic groups, or indolyl groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halo, CF_3 , OCF_3 , CN and nitro; and a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and a group of formula $-\text{CONR}''\text{R}'''$ and $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a piperidine, a piperazine or a morpholine ring.

In a yet more preferred embodiment

'A' represents a bivalent phenyl group of the formula




'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from




B represents a phenyl group; or

B represents a 5-membered aromatic monocyclic heterocyclic group selected from

13




B represents a 6-membered aromatic monocyclic heterocyclic group
5 selected from




B represents an indol-2-yl, an indol-3-yl, an indol-5-yl or an indol-6-yl group.

In a still more preferred embodiment 'A" represents a bivalent phenyl group of the formula



B represents a 5-membered aromatic monocyclic heterocyclic group selected from



wherein X represents O, S or Se; and R' represents hydrogen or alkyl;

which 5-membered aromatic monocyclic heterocyclic group is optionally substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF₃, CN and nitro.


In a most preferred embodiment the diazabicyclic biaryl derivative of the invention is

- 4-(6-Thien-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Pyridin-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Selenophen-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-Biphenyl-4-yl-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Furan-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Thien-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Furan-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Thiazol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Selenophen-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-(6-Indol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(6-Indol-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(6-Indol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(6-Indol-6-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 5 4-(6-oxazol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(6-oxazol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(6-thiazol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-[6-(1,3,4)-thiadiazol-2-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane; or
 4-[6-(1,3,4)-oxadiazol-2-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane;
 10 or an enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

In a fifth preferred embodiment the diazabicyclic biaryl derivative of the invention is a compound of Formula I or Formula II wherein

'A" represents a bivalent 5-membered aromatic monocyclic heterocyclic
 15 group selected from




wherein X represents O, S or Se; and R' represents hydrogen or alkyl; and

20 B represents a 5-6 membered aromatic monocyclic heterocyclic group; or
 B represents an aromatic bicyclic heterocyclic group;

which monocyclic or bicyclic heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and
 25 nitro; and a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form
 30 a heterocyclic ring.


In a more preferred embodiment

'A" represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




5 in the direction stated); and

B represents a 5-membered aromatic monocyclic heterocyclic group selected from



B represents a 6-membered aromatic monocyclic heterocyclic group selected from




15 which 5- or 6-membered aromatic monocyclic heterocyclic group is optionally substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy halo, CF_3 , OCF_3 , CN and nitro; and a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and a group of formula $-\text{CONR}''\text{R}'''$ and

20 $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen,


alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.

In an even more preferred embodiment


'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from



B represents a 5-membered aromatic monocyclic heterocyclic group selected from



15 B represents a 6-membered aromatic monocyclic heterocyclic group selected from



In a most preferred embodiment the diazabicyclic biaryl derivative of the invention is

- 20
- 4-(5-Thien-2-yl-pyrrol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 - 4-(5-Thien-2-yl-N-methyl-pyrrol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 - 4-(5-Thien-2-yl-thiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 - 4-(2-Thien-2-yl-thiazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
 - 4-(5-Thien-2-yl-furan-2-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-(5-Thien-2-yl-thien-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(5-Thien-2-yl-imidazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(5-Thien-2-yl-*N*-methyl-imidazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(2-Thien-2-yl-imidazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
 5 4-(2-Thien-2-yl-*N*-methyl-imidazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(5-Thien-2-yl-oxazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(2-Thien-2-yl-oxazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(5-Thien-2-yl-isoxazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 4-(5-Thien-2-yl-isothiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
 10 4-(3-Thien-2-yl-isoxazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane; or
 4-(3-Thien-2-yl-isothiazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
 or an enantiomer or a mixture of its enantiomers, or a pharmaceutically
 acceptable salt thereof.

Any combination of two or more of the embodiments described herein is
 15 considered within the scope of the present invention.

Definition of Substituents

In the context of this invention halo represents a fluorine, a chlorine, a
 bromine or an iodine atom. Thus, a trihalomethyl group represents e.g. a
 20 trifluoromethyl group, a trichloromethyl group and similar trihalo-substituted methyl
 groups.

In the context of this invention an alkyl group designates a univalent
 saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably
 contain of from one to eighteen carbon atoms (C₁₋₁₈-alkyl), more preferred of from one
 25 to six carbon atoms (C₁₋₆-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl,
 tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C₁₋₄-
 alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another
 preferred embodiment of this invention alkyl represents a C₁₋₃-alkyl group, which may
 in particular be methyl, ethyl, propyl or isopropyl.

30 In the context of this invention a cycloalkyl group designates a cyclic alkyl
 group, preferably containing of from three to seven carbon atoms (C₃₋₇-cycloalkyl),
 including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

In the context of this invention a cycloalkyl-alkyl group designates a
 cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl
 35 group as also defined above. Examples of preferred cycloalkyl-alkyl groups of the
 invention include cyclopropylmethyl and cyclopropylethyl.

In the context of this invention an alkoxy group designates an "alkyl-O-"
 group, wherein alkyl is as defined above. Examples of preferred alkoxy groups of the
 invention include methoxy and ethoxy.

In the context of this invention a cyanoalkyl group designates an “-alkyl-CN” group, wherein alkyl is as defined above.

In the context of this invention an aromatic monocyclic or bicyclic carbocyclic group designates a monocyclic or polycyclic aromatic hydrocarbon group.

5 Examples of preferred aryl groups of the invention include phenyl, indenyl, naphthyl, azulenyl, fluorenyl, and anthracenyl.

In the context of this invention a 5-6 membered aromatic monocyclic heterocyclic designates a 5-6 membered heteroaryl, which holds one or more heteroatoms in its ring structure. Preferred heteroatoms include nitrogen (N), oxygen
10 (O), and sulphur (S).

Preferred 5-6 membered heteroaryl groups of the invention include furanyl, in particular 2- or 3-furanyl; thienyl, in particular 2 or 3-thienyl; selenophenyl, in particular 2- or 3-selenophenyl; pyrrolyl (azolyl), in particular 2 or 3-pyrrolyl; oxazolyl, in particular oxazol-2,4 or 5-yl; thiazolyl, in particular thiazol-2,4 or 5-yl;
15 imidazolyl, in particular 2 or 4-imidazolyl; pyrazolyl, in particular 3 or 4-pyrazolyl; isoxazolyl, in particular isoxazol-3,4 or 5-yl; isothiazolyl, in particular isothiazol-3,4 or 5-yl; oxadiazolyl, in particular 1,2,3-oxadiazol-4 or 5-yl, or 1,3,4-oxadiazol-2-yl; triazolyl, in particular 1,2,3-triazol-4-yl or 1,2,4-triazol-3-yl; thiadiazolyl, in particular 1,2,3-thiadiazol-4 or 5-yl, or 1,3,4-thiadiazol-2-yl; pyridinyl, in particular 2,3 or 4-
20 pyridinyl; pyridazinyl, in particular 3 or 4-pyridazinyl; pyrimidinyl, in particular 2,4 or 5-pyrimidinyl; pyrazinyl, in particular 2 or 3-pyrazinyl; and triazinyl, in particular 1,2,4- or 1,3,5-triazinyl.

In the context of this invention an aromatic bicyclic heterocyclic group designates a bicyclic heterocyclic group, which holds one or more heteroatoms in its
25 ring structure. In the context of this invention the term “bicyclic heterocyclic group” includes benzo-fused five- and six-membered heterocyclic rings containing one or more heteroatoms. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).

Preferred bicyclic heteroaryl groups of the invention include indoliziny, in
30 particular 2,5 or 6-indoliziny; indolyl, in particular 2,5 or 6-indolyl; isoindolyl, in particular 2,5 or 6-isoindolyl; benzo[b]furanyl, in particular 2,5 or 6-benzofuranyl; benzo[b]thienyl, in particular 2,5 or 6-benzothienyl; benzoimidazolyl, in particular 2,5 or 6-benzoimidazolyl; benzothiazolyl, in particular 5 or 6-benzothiazolyl; purinyl, in particular 2 or 8-purinyl; quinolinyl, in particular 2,3,6 or 7-quinolinyl; isoquinolinyl, in
35 particular 3,6 or 7-isoquinolinyl; cinnolinyl, in particular 6 or 7-cinnolinyl; phthalazinyl, in particular 6 or 7-phthalazinyl; quinazolinyl, in particular 2,6 or 7-quinazolinyl; quinoxalinyl, in particular 2 or 6-quinoxalinyl; 1,8-naphthyridinyl, in particular 1,8-naphthyridin-2,3,6 or 7-yl; and pteridinyl, in particular 2,6 or 7-pteridinyl.

Pharmaceutically Acceptable Salts


The diazabicyclic biaryl derivative of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical
5 compound of the invention.

Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the
10 benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate derived, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by
15 procedures well known and described in the art.

Metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.

In the context of this invention the "onium salts" of N-containing compounds
20 are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.

Particularly preferred onium salts of the invention include those created at the N' position according to the following formula I'



Steric Isomers

The chemical compounds of the present invention may exist in (+) and (-) forms as well as in racemic forms. The racemates of these isomers and the individual
30 isomers themselves are within the scope of the present invention.

Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical
35 antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes,

e.g., by fractional crystallisation of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example.

The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.

Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by *Jaques J, Collet A, & Wilen S* in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

Optical active compounds can also be prepared from optical active starting materials.

15 **Methods of Producing Diazabicyclic Biaryl Derivatives**

The diazabicyclic biaryl derivative of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.

Also one compound of the invention can be converted to another compound of the invention using conventional methods.

The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.

Biological Activity

The present invention relates to novel diazabicyclic biaryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors (nAChR), and modulators of the monoamine receptors, in particular the biogenic amine transporters such as the serotonin receptor (5-HT_R), the dopamine receptor (DAR) and the norepinephrine receptor (NER), and of the biogenic amine transporters for serotonin (5-HT), dopamine (DA) and norepinephrine (NE). Also preferred diazabicyclic biaryl derivatives of the invention show selective $\alpha 7$ activity.

In the context of this invention the term "modulator" covers agonists, partial agonists, antagonists and allosteric modulators of the receptor.

Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or conditions as diverse as CNS related diseases, PNS related diseases, diseases related to smooth muscle contraction, endocrine

disorders, diseases related to neuro-degeneration, diseases related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

In a preferred embodiment the compounds of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system. Such diseases or disorders includes anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.

In another preferred embodiment the compounds of the invention may be useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.

In yet another preferred embodiment the compounds of the invention may be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

In still another preferred embodiment the compounds of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.

In even another preferred embodiment the compounds of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

In still another preferred embodiment the compounds of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.

Finally the compounds of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine-containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like

drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.

5 In this context "treatment" covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a voluntary diminished intake of the addictive substance.

In another aspect, the compounds of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various
10 tissues.

Pharmaceutical Compositions

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the diazabicyclic biaryl derivative of
15 the invention.

While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers,
20 buffers, diluents, and/or other customary pharmaceutical auxiliaries.

In a preferred embodiment, the invention provides pharmaceutical compositions comprising the diazabicyclic biaryl derivative of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic
25 and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

The pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy. Preferred routes of
30 administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition of the invention can be manufactured by any skilled person by use of standard methods and conventional techniques appropriate to the desired formulation.
35 When desired, compositions adapted to give sustained release of the active ingredient may be employed.

Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

The actual dosage depend on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.

The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 $\mu\text{g/kg}$ i.v. and 1 $\mu\text{g/kg}$ p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 $\mu\text{g/kg}$ to about 10 mg/kg/day i.v., and from about 1 $\mu\text{g/kg}$ to about 100 mg/kg/day p.o.

Methods of Therapy

The diazabicyclic biaryl derivatives of the present invention are valuable nicotinic and monoamine receptor modulators, and therefore useful for the treatment of a range of ailments involving cholinergic dysfunction as well as a range of disorders responsive to the action of nAChR modulators.

In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a diazabicyclic biaryl derivative of the invention.

In the context of this invention the term "treatment" covers treatment, prevention, prophylaxis or alleviation, and the term "disease" covers illnesses, diseases, disorders and conditions related to the disease in question.

The preferred indications contemplated according to the invention are those stated above.

It is at present contemplated that suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.

A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o. The upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.

EXAMPLES

The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

Example 1

Preparatory Example

All reactions involving air sensitive reagents or intermediates were performed under nitrogen and in anhydrous solvents. Magnesium sulfate was used as drying agent in the workup-procedures and solvents were evaporated under reduced pressure.

1,4-Diazabicyclo[3.2.2]nonane (Intermediate compound)

Was prepared according to J. Med. Chem. 1993 **36** 2311-2320 and the following slightly modified method.

To a solution of 1,4-diazabicyclo[3.2.2]nonan-3-one (15.8 g, 113 mmol) in absolute dioxane (130 ml), LiAlH_4 (4.9 g, 130 mmol) was added under argon. The mixture was refluxed for 6 hours and then allowed to reach room temperature. To this reaction mixture, water (5 ml in 10 ml of dioxane) was added, by drops, the mixture was stirred for 0.5 hour and then filtered off via glass filter. The solvent was evaporated and the residue was distilled using a Kugelrohr apparatus at 90°C (0.1 mbar) to yield 1,4-diazabicyclo[3.2.2]nonane (11.1 g, 78%) as colourless hygroscopic material.

1,4-Diazabicyclo[3.2.2]nonan-3-one (Intermediate compound)

To a solution of 3-quinuclidinone hydrochloride (45g, 278 mmol) in 90 ml of water, hydroxylamine hydrochloride (21 g, 302 mmol) and sodium acetate ($\text{CH}_3\text{COOH} \times 3\text{H}_2\text{O}$, 83 g, 610 mmol) were added, and the mixture was stirred at 70°C for 1 hour, and then cooled to 0°C. The separated crystalline material was filtered off (without washing) and dried *in vacuo* to yield 40.0 g of oxime.

The 3-quinuclidinone oxime (40.0 g) was added by small portions during 2 hours to polyphosphoric acid* (190 g), preheated to 120°C. During the reaction the temperature of the solution was kept at 130°C. After addition of all the oxime, the solution was stirred for 20 minutes at the same temperature, then transferred to an enamelled vessel and allowed to reach room temperature. The acidic mixture was neutralized by a solution of potassium carbonate (500 g in 300 ml of water), transferred into 2000 ml flask, diluted with 300 ml of water and extracted with

chloroform (3 x 600 ml). The combined organic extracts were dried with sodium sulphate, the solvent evaporated, and the solid residue dried up *in vacuo* to yield 30.0 g (77%) of a mixture of lactams.

Crystallization of the obtained mixture from 1,4-dioxane (220 ml) gave 15.8 g (40.5%) of 1,4-diazabicyclo[3.2.2]nonan-3-one as colourless large crystals with mp 211-212°C.

The filtrate was evaporated and the residue was chromatographed on a silica gel column (Merck, 9385, 230-400 mesh) with acetone as eluent. The solvent was evaporated and the residue recrystallised from ethyl etanoate to yield 1,3-diazabicyclo[3.2.2]nonan-4-one (10.2 g, 26%) as colourless fine crystals with mp 125-126°C.

Polyphosphoric acid*

85% Orthophosphoric acid (500 g, 294 ml, 4.337 mol) was placed into a 2000 ml flask and phosphor pentoxide (750 g, 5.284 mol) was added at room temperature (ratio acid-pentoxide, 2:3). The mixture was stirred at 200-220°C for 2 hours to yield of 1250 g of polyphosphoric acid, containing 80% of P₂O₅.

3-Bromo-6-thien-3-yl-pyridazine (Intermediate compound)

A mixture of 3,6-dibromo-pyridazine (8.45 g, 35.5 mmol), palladacycle (0.66 g, 0.71 mmol), palladium acetate (0.16 g, 0.71 mmol), tri-*tert*-butylphosphine (0.35 ml, 1.42 mmol), aqueous potassium carbonate (2 M, 107 mmol), 1,3-propanediol (7.7 ml, 107 mmol) and 1,4-dioxane (100 ml) was stirred at reflux for 1 hour. 3-Thienyl boronic acid (5.0 g, 39.0 mmol) was added and the mixture was stirred at reflux for 7 days. Aqueous sodium hydroxide (50 ml, 1M) was added and the mixture was extracted with ethyl acetate (2 x 100 ml). Chromatography on silica gel with ethyl acetate : petroleum (1 : 3) as solvent gave the title compound. Yield 1.5 g (18%).

3-Chloro-6-thien-3-yl-pyridazine hydrochloric acid salt (Intermediate compound)

A mixture of 3-bromo-6-thien-3-yl-pyridazine (1.39 g, 5.8 mmol) and conc. hydrochloric acid (25 ml) was stirred at reflux for 4.5 hours. The reaction mixture was evaporated and the product was isolated in quantitative yield (1.35 g, 5.8 mmol).

4-(6-Bromo-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt

(Intermediate compound)

A mixture of 3,6-dibromo-pyridazine (3.77 g, 15.85 mmol) 1,4-diazabicyclo[3.2.2]nonane (2.00 g, 15.85 mmol) and aqueous sodium hydroxide (10 ml, 4M) was stirred at 100°C for 30 minutes. The mixture was extracted with dichloromethane (3 x 20 ml). Chromatography on silica gel with dichloromethane, 10%

methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. Yield 0.88 g, 20%.

4-[6-Thien-3-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt

5 (Compound 1)

A mixture of 1,4-diazabicyclo[3.2.2]nonane (0.54 g, 4.29 mmol), 3-chloro-6-thien-3-yl-pyridazine hydrochloric acid salt (1.00 g, 4.29 mmol), triethylamine (3.00 ml, 21.4 mmol) and dioxane (15 ml) was stirred at reflux for 40 hours. Aqueous sodium hydroxide (1 M, 25 ml) was added and the mixture was extracted twice with ethyl acetate (2 x 20 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9 : 1) saturated with fumaric acid. Yield 0.11 g, 9%. Mp 153.7°C.

15 Method A

4-(6-Pyridin-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 2)

A mixture of 4-(6-bromo-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane (0.49 g, 1.7 mmol), diethyl-3-pyridylborane (0.38 g, 2.6 mmol), aqueous potassium carbonate (2.6 ml, 2M), palladium(0)tetrakis(triphenyl)phosphine (59 mg, 0.051 mmol), 1,3-propanediol (0.37 ml, 5.1 mmol) and dioxane (5 ml) was stirred at reflux for 15 hours. The mixture was evaporated. Aqueous sodium hydroxide (10 ml, 4M) was added. The mixture was extracted with dichloromethane (3 x 20 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. Yield 0.10 g, 21%.

The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9 : 1) saturated with fumaric acid. Mp 170.2-171.6°C.

Method B

30 4-(6-Selenophen-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 3)

A mixture of 4-(6-bromo-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane (1.1 g, 3.9 mmol), 3-trimethylstannylselenophene (2.3 g, 7.8 mmol), PdCl₂(PPh₃)₂ (82 mg, 0.11 mmol) and DMF (1 ml) was stirred at 100°C for 15 hours. Aqueous sodium hydroxide (10 ml, 4M) was added. The mixture was extracted with dichloromethane (3 x 20 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. Yield 0.14 g, 11%.

The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9 : 1) saturated with fumaric acid. Mp 181.2-182.2°C.

4-(6-Thien-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 4)

Was prepared according to Method B from 2-trimethylstannylthiophene. Mp
5 185.5-187.4°C.

4-(6-Selenophen-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 5)

Was prepared according to Method B from 2-trimethylstannylselenophene.
10 Mp 194.7-195.9°C.

4-(6-Furan-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 6)

Was prepared according to Method B from 2-trimethylstannylfuran. Mp
15 155.7-156.1°C.

4-(6-Furan-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 7)

Was prepared according to Method B from 3-trimethylstannylfuran. Mp
20 116.9-119.0°C.

4-(6-Thiazol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 8)

Was prepared according to Method B from 2-thiazolylzinc chloride. Mp
25 175.2-179.2°C.

In analogy herewith the following compounds are prepared:

4-(5-Thien-2-yl-pyrrol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 9);

30 4-(5-Thien-2-yl-N-methyl-pyrrol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 10);

4-(5-Thien-2-yl-thiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 11);

4-(2-Thien-2-yl-thiazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
35 (Compound 12);

4-(5-Thien-2-yl-furan-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 13);

4-(5-Thien-2-yl-thien-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 14);

- 4-(5-Thien-2-yl-imidazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 15);
- 4-(5-Thien-2-yl-*N*-methyl-imidazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 16);
- 5 4-(2-Thien-2-yl-imidazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 17);
- 4-(2-Thien-2-yl-*N*-methyl-imidazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 18);
- 4-(5-Thien-2-yl-oxazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
10 (Compound 19);
- 4-(2-Thien-2-yl-oxazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 20);
- 4-(5-Thien-2-yl-isoxazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 21);
- 15 4-(5-Thien-2-yl-isothiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 22);
- 4-(3-Thien-2-yl-isoxazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 23);
- 4-(3-Thien-2-yl-isothiazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
20 (Compound 24);
- 4-(6-Indol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 25);
- 4-(6-Indol-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 26);
- 25 4-(6-Indol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 27);
- 4-(6-Indol-6-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 28);
- 4-(6-oxazol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
30 (Compound 29);
- 4-(6-oxazol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 30);
- 4-(6-thiazol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt
(Compound 31);
- 35 4-[6-(1,3,4)-thiadiazol-2-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid
salt (Compound 32); and
- 4-[6-(1,3,4)-oxadiazol-2-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid
salt (Compound 33).

4-Biphenyl-4-yl-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound 34)

A mixture of 1,4-diazabicyclo[3.2.2]nonane (1.0 g, 7.9 mmol), 4-bromobiphenyl (1.85 g, 7.9 mmol), potassium *tert*-butoxide (1.85 g, 15.8 mmol), Pd(0)(PPh₃)₄ (0.27 g, 0.24 mmol) and dioxane (10 ml) was stirred at 100°C for 15 hours. The mixture was evaporated. Aqueous sodium hydroxide (10 ml, 4M) was added. The mixture was extracted with dichloromethane (3 x 20 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. Yield 65 mg, 3%.

The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9 : 1) saturated with fumaric acid. Mp 196.3-196.9°C.

Example 2***In vitro* Inhibition of ³H- α -Bungarotoxine Binding in Rat Brain**

In this example the affinity of the compounds of the invention for binding to α_7 -subtype of nicotinic receptors is determined.

α -Bungarotoxine is a peptide isolated from the venom of the Elapidae snake *Bungarus multicinctus*. It has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist.

³H- α -Bungarotoxine labels nicotinic acetylcholine receptors formed by the α_7 subunit isoform found in brain and the α_1 isoform in the neuromuscular junction.

Tissue preparation

Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-250 g) are homogenised for 10 seconds in 15 ml of 20 mM Hepes buffer containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO₄ and 2.5 mM CaCl₂ (pH 7.5) using an Ultra-Turrax homogeniser. The tissue suspension is subjected to centrifugation at 27,000 x g for 10 minutes. The supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 minutes in 20 ml of fresh buffer, and the final pellet is then re-suspended in fresh buffer containing 0.01% BSA (35 ml per g of original tissue) and used for binding assays.

Assay

Aliquots of 500 μ l of homogenate are added to 25 μ l of test solution and 25 μ l of ³H- α -bungarotoxine (2 nM, final concentration) and mixed and incubated for 2 hours at 37°C. Non-specific binding is determined using (-)-nicotine (1 mM, final concentration). After incubation, the samples are added 5 ml of ice-cold Hepes buffer containing 0.05% PEI and poured directly onto Whatman GF/C glass fibre filters (pre-soaked in 0.1% PEI for at least 6 hours) under suction, and immediately washed with 2 x 5 ml ice-cold buffer.

The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

The test value is given as an IC_{50} (the concentration of the test substance which inhibits the specific binding of 3H - α -bungarotoxin by 50%).

The results of these experiments are presented in Table 1 below.


Table 1

Inhibition of 3H - α -Bungarotoxine Binding

Compound No.	IC_{50} (μM)
1	0.038
4	0.044
5	0.0065
7	0.022
34	0.024

CLAIMS


1. A diazabicyclic biaryl derivative represented by Formula I




any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein

n is 1, 2 or 3; and

'A' represents a bivalent phenyl group of the formula




'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




wherein X represents O, S or Se; and

R' represents hydrogen or alkyl; or

'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from





B represents an aromatic monocyclic or bicyclic carbocyclic group; or

5 B represents a 5-6 membered aromatic monocyclic heterocyclic group; or

B represents an aromatic bicyclic heterocyclic group;

which monocyclic or bicyclic, carbocyclic or heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of

- 10 - alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and
- a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- 15 - a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring;

20 provided however,

if A represents an isoxazol-3,5-diyl, a thiazol-2,5-diyl, a 1,2,4-oxadiazol-3,5-diyl, a 1,3,4-oxadiazol-2,5-diyl, a 1,3,4-thiadiazol-2,5-diyl, pyridin-2,5-diyl, or a pyridazin-3,6-diyl group,


then B is not a phenyl or substituted phenyl group; or

25 if A represents a 1,2,4-oxadiazol-3,5-diyl group,

then B is not a substituted or non-substituted thienyl, furanyl, pyridinyl, or benzothienyl group.

2. The diazabicyclic biaryl derivative of claim 1, represented by Formula II

30



wherein 'A' is as defined in claim 1; and


B represents a 5-6 membered aromatic monocyclic heterocyclic group; or

B represents an aromatic bicyclic heterocyclic group;

which monocyclic or bicyclic heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of


- alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and
- a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring.

The diazabicyclic biaryl derivative of claim 1, represented by Formula II



wherein

'A" represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




wherein X represents O, S or Se; and

R' represents hydrogen or alkyl; and

B represents an aromatic monocyclic or bicyclic carbocyclic group, which monocyclic or bicyclic carbocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of

- alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and
- a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring.


4. The diazabicyclic biaryl derivative of claim 3, wherein 'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from



B represents a phenyl or naphthyl group, which aromatic group may optionally be substituted one or two times with substituents selected from the group consisting of

- alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and
- a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.


5. The diazabicyclic biaryl derivative of claim 4, wherein 'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




B represents a phenyl or naphthyl group, which aromatic group may optionally be substituted one or two times with substituents selected from the group consisting of

- 10 - alkyl, alkoxy, halo, CF_3 , OCF_3 , CN and nitro; and
 - a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and
 - a group of formula $-\text{CONR}''\text{R}'''$ and $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl, or
 15 wherein R'' and R''' , together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.

6. The diazabicyclic biaryl derivative of either of claims 1-2, wherein 'A' represents a bivalent phenyl group of the formula



'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from



B represents an aromatic monocyclic or bicyclic carbocyclic group; or
 B represents a 5-6 membered aromatic monocyclic heterocyclic group; or

B represents an aromatic bicyclic heterocyclic group;
which monocyclic or bicyclic, carbocyclic or heterocyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of


- alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF_3 , OCF_3 , CN, amino and nitro; and
- a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- a group of formula $-\text{CONR}''\text{R}'''$ and $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a heterocyclic ring.

7. The diazabicyclic biaryl derivative of claim 6, wherein
'A' represents a bivalent phenyl group of the formula




; or


'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from




, and




, and




, and



, and



, and




(read in the


direction stated); and

B represents a phenyl or naphthyl group; or


B represents a 5-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




, and



, and




, and



, and


37



wherein X represents O, S or Se; and

R' represents hydrogen or alkyl; or

5 B represents a 6-membered aromatic monocyclic heterocyclic group selected from



; or


10 B represents an indolyl group;

which phenyl or naphthyl groups, or 5-6-membered monocyclic heterocyclic groups, or indolyl group may optionally be substituted one or more times with substituents selected from the group consisting of

- alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN, amino and nitro; and
- a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''', together with the N-atom to which they are bound, form a heterocyclic ring.

8. The diazabicyclic biaryl derivative of claim 7, wherein


'A' represents a bivalent phenyl group of the formula



; or


'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from

38




B represents a phenyl group; or

B represents a 5-membered aromatic monocyclic heterocyclic group selected from



B represents a 6-membered aromatic monocyclic heterocyclic group selected from




B represents an indol-2-yl, an indol-3-yl, an indol-5-yl or an indol-6-yl group;

which phenyl group, or 5-6-membered monocyclic heterocyclic groups, or indolyl groups may optionally be substituted one or more times with substituents selected from the group consisting of


- alkyl, alkoxy, halo, CF_3 , OCF_3 , CN and nitro; and
- a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and
- a group of formula $-\text{CONR}''\text{R}'''$ and $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.

9. The diazabicyclic biaryl derivative of claim 8, wherein 'A' represents a bivalent phenyl group of the formula




; or


'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from



, and



, and




(read in the


direction stated); and

B represents a phenyl group; or


B represents a 5-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




, and




, and




, and




, and




, and




, and




, and




, and




, and



, and




, and




; or


B represents a 6-membered aromatic monocyclic heterocyclic group selected from




, and



, and



, and



; or

B represents an indol-2-yl, an indol-3-yl, an indol-5-yl or an indol-6-yl group;


which phenyl group, or 5-6-membered monocyclic heterocyclic groups, or indolyl groups may optionally be substituted one or more times with substituents selected from the group consisting of

- alkyl, alkoxy, halo, CF₃, OCF₃, CN and nitro; and
- a group for formula -NR''COR''', and -NR''SO₂R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl or phenyl; and
- a group of formula -CONR''R''' and -SO₂NR''R''', wherein R'' and R''', independently of one another represents hydrogen, alkyl or phenyl, or

wherein R'' and R''', together with the N-atom to which they are bound, form a piperidine, a piperazine or a morpholine ring.


10. The diazabicyclic biaryl derivative of claim 9, wherein

5 'A' represents a bivalent phenyl group of the formula




; or


'A' represents a bivalent 6-membered aromatic monocyclic carbocyclic or heterocyclic group selected from



, and



, and




(read in the


10 direction stated); and

B represents a phenyl group; or


B represents a 5-membered aromatic monocyclic heterocyclic group selected from




, and




, and




, and




, and




, and




, and




, and




, and




, and



, and




, and




; or


B represents a 6-membered aromatic monocyclic heterocyclic group selected from



, and



, and



; or

B represents an indol-2-yl, an indol-3-yl, an indol-5-yl or an indol-6-yl group.

11. The diazabicyclic biaryl derivative of claim 10, which is

4-(6-Thien-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-(6-Pyridin-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;


4-(6-Selenophen-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-Biphenyl-4-yl-1,4-diazabicyclo[3.2.2]nonane;

4-(6-Furan-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-(6-Thien-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Furan-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Thiazol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Selenophen-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Indol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Indol-3-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Indol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-Indol-6-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-oxazol-2-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-oxazol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-(6-thiazol-5-yl-pyridazin-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
4-[6-(1,3,4)-thiadiazol-2-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane; or
4-[6-(1,3,4)-oxadiazol-2-yl-pyridazin-3-yl]-1,4-diazabicyclo[3.2.2]nonane;
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

12. The diazabicyclic biaryl derivative of either of claims 1-2, wherein 'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




wherein X represents O, S or Se; and
R' represents hydrogen or alkyl; and

B represents a 5-6 membered aromatic monocyclic heterocyclic group; or
B represents an aromatic bicyclic heterocyclic group;
which monocyclic or bicyclic heterocyclic groups may optionally be substituted
one or more times with substituents selected from the group consisting of
- alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cyanoalkyl, halo, CF₃, OCF₃, CN,
amino and nitro; and


- a group for formula $-NR''COR'''$, and $-NR''SO_2R'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl; and
- a group of formula $-CONR''R'''$ and $-SO_2NR''R'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a heterocyclic ring.

13. The diazabicyclic biaryl derivative of claim 12, wherein


'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




B represents a 5-membered aromatic monocyclic heterocyclic group selected from



43



B represents a 6-membered aromatic monocyclic heterocyclic group selected from




which 5- or 6-membered aromatic monocyclic heterocyclic group is optionally substituted one or two times with substituents selected from the group consisting of


- alkyl, alkoxy halo, CF_3 , OCF_3 , CN and nitro; and
- a group for formula $-\text{NR}''\text{COR}'''$, and $-\text{NR}''\text{SO}_2\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl; and
- a group of formula $-\text{CONR}''\text{R}'''$ and $-\text{SO}_2\text{NR}''\text{R}'''$, wherein R'' and R''' , independently of one another represents hydrogen, alkyl or phenyl, or wherein R'' and R''' , together with the N-atom to which they are bound, form a piperidine, a piperazine, a morpholine or a thiomorpholine ring.

14. The diazabicyclic biaryl derivative of claim 13, wherein


'A' represents a bivalent 5-membered aromatic monocyclic heterocyclic group selected from




44



B represents a 5-membered aromatic monocyclic heterocyclic group selected from



B represents a 6-membered aromatic monocyclic heterocyclic group selected from



15. The diazabicyclic biaryl derivative of claim 14, which is
- 4-(5-Thien-2-yl-pyrrol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-*N*-methyl-pyrrol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-thiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(2-Thien-2-yl-thiazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-furan-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-thien-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-imidazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-*N*-methyl-imidazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(2-Thien-2-yl-imidazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(2-Thien-2-yl-*N*-methyl-imidazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-oxazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(2-Thien-2-yl-oxazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-isoxazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(5-Thien-2-yl-isothiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane;
- 4-(3-Thien-2-yl-isoxazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane; or
- 4-(3-Thien-2-yl-isothiazol-5-yl)-1,4-diazabicyclo[3.2.2]nonane;

or an enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a therapeutically effective amount of a
5 diazabicyclic biaryl derivative of any of claims 1-15, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
17. Use of a diazabicyclic biaryl derivative of any of claims 1-15, or a
10 pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition/medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors.
18. The use according to claim 17, wherein the disease, disorder or condition relates
15 to the central nervous system.
19. The use according to claim 18, wherein the disease, disorder or condition is
20 anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as
25 anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and
30 jet-lag.
20. The use according to claim 17, wherein the disease, disorder or condition are
associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy,
35 tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
21. The use according to claim 17, wherein the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

22. The use according to claim 17, wherein the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neurodegeneration.

5

23. The use according to claim 17, wherein the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

10

24. The use according to claim 17, wherein the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.

15 25. The use according to claim 17, wherein the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine-containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.

20

26. A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a diazabicyclic biaryl derivative of any of claims 1-15.

25

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 03/00769

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/08 A61K31/551 A61P25/00 A61P25/28 A61P25/16
 //(C07D471/08,243:00,237:00,261:00,275:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 34279 A (SANOFI SYNTHELABO ; JEUNESSE JEAN (FR); NEDELEC ALAIN (FR); EVEN LU) 15 June 2000 (2000-06-15) see also compounds 13 and 27 ---	1-26
X	WO 01 92259 A (SANOFI SYNTHELABO ; LECLERC ODILE (FR); GALLI FREDERIC (FR); LOCHEA) 6 December 2001 (2001-12-06) see also compound 15 ---	1-26
X	WO 01 92260 A (SANOFI SYNTHELABO ; LECLERC ODILE (FR); GALLETT THIERRY (FR); GALLI) 6 December 2001 (2001-12-06) the whole document --- -/--	1-26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 February 2004

Date of mailing of the international search report

26. 03. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

EVA JOHANSSON /EÖ

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 03/00769

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 92261 A (SANOFI SYNTHELABO ;SAMSON AXELLE (FR); GALLI FREDERIC (FR); LOCHEA) 6 December 2001 (2001-12-06) the whole document ---	1-26
P,A	DE 101 62 442 A (BAYER AG) 3 July 2003 (2003-07-03) the whole document ---	1-26
A	EP 1 219 622 A (PFIZER PROD INC) 3 July 2002 (2002-07-03) the whole document ---	1-26
P,A	WO 03 044019 A (SANOFI SYNTHELABO ;LECLERC ODILE (FR); GALLI FREDERIC (FR); LOCHEA) 30 May 2003 (2003-05-30) the whole document ---	1-26
P,A	WO 03 044020 A (SANOFI SYNTHELABO ;LECLERC ODILE (FR); GALLI FREDERIC (FR); LOCHEA) 30 May 2003 (2003-05-30) the whole document ---	1-26
P,A	WO 03 044024 A (SANOFI SYNTHELABO ;LECLERC ODILE (FR); GALLI FREDERIC (FR); LOCHEA) 30 May 2003 (2003-05-30) the whole document -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 03/00769

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 26

Claim 26 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 03/00769

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0034279	A	15-06-2000	FR 2786770 A1 AT 249460 T AU 1393000 A DE 69911241 D1 EP 1135389 A1 WO 0034279 A1 JP 2002531565 T US 6407095 B1	09-06-2000 15-09-2003 26-06-2000 16-10-2003 26-09-2001 15-06-2000 24-09-2002 18-06-2002
WO 0192259	A	06-12-2001	FR 2809731 A1 AU 6404201 A EP 1289986 A1 WO 0192259 A1 HU 0302115 A2 JP 2003535089 T US 2003114461 A1	07-12-2001 11-12-2001 12-03-2003 06-12-2001 28-10-2003 25-11-2003 19-06-2003
WO 0192260	A	06-12-2001	FR 2809732 A1 AU 6404301 A EP 1289987 A1 WO 0192260 A1 HU 0302157 A2 JP 2003535090 T	07-12-2001 11-12-2001 12-03-2003 06-12-2001 28-10-2003 25-11-2003
WO 0192261	A	06-12-2001	FR 2809730 A1 AU 6404401 A EP 1289988 A1 WO 0192261 A1 HU 0302193 A2 JP 2003535091 T TW 541307 B US 2003153574 A1	07-12-2001 11-12-2001 12-03-2003 06-12-2001 28-11-2003 25-11-2003 11-07-2003 14-08-2003
DE 10162442	A	03-07-2003	DE 10162442 A1	03-07-2003
EP 1219622	A	03-07-2002	BR 0106462 A CA 2366268 A1 EP 1219622 A2 JP 2002255965 A US 2002086871 A1 US 2003119837 A1	24-09-2002 29-06-2002 03-07-2002 11-09-2002 04-07-2002 26-06-2003
WO 03044019	A	30-05-2003	FR 2832712 A1 WO 03044019 A1	30-05-2003 30-05-2003
WO 03044020	A	30-05-2003	FR 2832713 A1 WO 03044020 A1	30-05-2003 30-05-2003
WO 03044024	A	30-05-2003	FR 2832714 A1 WO 03044024 A1	30-05-2003 30-05-2003